Amicus Repositions With A Focus On Combining Chaperones With ERTs
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech re-obtains all rights to migalastat from GSK, buys out ERT specialist Callidus and will raise $40 million through a private placement and a debt financing. Callidus co-founder, a former Genzyme scientist, will take over the Amicus’ scientific team, while the company slashes its overall headcount by 14%.
You may also be interested in...
Persistence Pays Off For Amicus: Positive Migalastat Data In Hand
Amicus will return to FDA with positive data on its oral small molecule chaperone migalastat in Fabry patients after a Phase III trial showed the oral drug had comparable efficacy to existing enzyme replacement therapies.
Still Hopeful About Migalastat, Amicus Also Pursuing Optimized Enzyme Replacement Therapies
Amicus’ most promising candidate would improve upon Sanofi/Genzyme’s Pompe disease drug Lumizyme, but closer to the clinic is a program to combine Fabry disease candidate migalastat with an enzyme replacement therapy obtained in last year’s buyout of Callidus.
Deals Of The Week Wonders: Will Pharma Ever Pay More For Companion Diagnostics?
Partnerships between Lilly/Qiagen and BioMarin/Myriad highlight the increasing pace of deals to develop companion diagnostics as the importance of biomarkers and tests to drug development increases. In other deals Clovis buys Eos, Amicus buys Callidus and Versant gives Celgene and Bayer options to acquire drug assets.